Current Treatment
Currently, no treatment is available to prevent the development of AD. Instead, there are a few treatment options to help reduce symptoms in patients with mild-to-moderate forms of AD. Symptoms associated with disease progression include loss of memory, loss of cognitive function, and loss of judgment or the ability to solve problems. Cholinesterase inhibitors including donepezil, galantamine, and rivastigmine help by inhibiting the breakdown of acetylcholine at the synaptic cleft in turn increasing neuronal function and reducing symptoms. Memantine, an N-methyl-d-aspartate (NMDA) antagonist, has also been shown to improve mental status scores with minimal risk of side effects in patients with moderate-to-severe AD. 3
New Treatment Options
A definitive pathophysiology on the development of AD has not been determined. One theory is that AD is due to the buildup of beta amyloid plaques on the neuronal surfaces in the brain. 4 Others feel the disease is a result of the entanglement of neurons caused by the degeneration and destruction of Tau proteins. 5 However, both groups can agree that both beta amyloid and Tau protein play a key role in AD development and progression.
Beta Amyloid Plaques
Beta Secretase (BACE) inhibitors (Table 1) are drugs that have been in development over the past few years. These drugs target the enzyme Beta-secretase, which is responsible for one of the 2 important cleavage steps in the formation of amyloid-β peptides. 6 The accumulation of these amyloid-β peptides is what researchers have theorized to be one of the essential causes for the development of AD. 5 Unfortunately, recent Phase III studies, such as a late-phase verubecestat study, have not shown a benefit to patients with established mild-to-moderate AD. Results such as these are forcing drug companies to look into new target areas for the disease. However, a few BACE inhibitors still have ongoing trials in early AD. Researchers are hoping that by catching the buildup of beta amyloid early, they will stop the progression 735642H PXXXX10.1177/0018578717735642Hospital PharmacyOrf and Walker 
Tau Protein Targeting Drugs
Because of disappointments with BACE inhibitors, Tau protein targeting drugs (Table 2 ) are becoming the new hope to finally solve AD. Tau protein is a protein responsible for maintaining the structure of neurons by supporting microtubules. 5 In AD, the Tau protein becomes hyperphosphorylated and begins to form tangles. 5 These tangles can cause the neurons to lose their ability to communicate and to receive nutrients causing the neuron to decay and degenerate. 5 This loss of neuron function is what many believe to be one of the leading causes of AD. Leuco-methylthioninium-bis(hydromethanesulfonate) Source. Information adapted from the Prescribe Right Pharmaceutical Pipeline Tracker database. 7 Note. LMTX = leuco-methylthioninium-bis(hydromethanesulfonate); AD = Alzheimer's disease, ADAS-Cog 11 = Alzheimer's Disease Assessment Scale; ADCS-CGIC = Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change Scale
